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ABSTRACT OF THESIS 
 
 
THYMOQUINONE: THE EVALUATION OF ITS CYTOTOXIC POTENTIAL, EFFECTS 
ON P53 STATUS AND THE CELL CYCLE IN VARIOUS CANCER  
CELL LINES 
 
Cancer is a group of diseases that are the second leading cause of human 
mortality in the United States. Discovering new therapies is vital to conquer cancer. 
Thymoquinone (TQ) is found in the plant Nigella sativa. TQ was found to be cytotoxic to 
the human ovarian cancer cell lines PA-1, CAOV-3 and SKOV-3, which have varying 
p53 status. PA-1 cells were the most sensitive, indicating that TQ was effective against 
cells having wild-type (WT) p53. Western blots indicated an increase in p53 in cell lines 
having WT p53. TQ when given concurrently with cisplatin resulted in antagonism for 
PA-1, A172 and H460 cell lines. Sequential exposure to TQ followed by cisplatin 
resulted in synergy or additive effects in these cell lines. Sequential exposure to 
cisplatin followed by TQ resulted in additive or moderate antagonism in these cell lines. 
Concurrent exposure to TQ and paclitaxel showed synergy in PA-1 and H460 cells. 
Sequential exposure to TQ followed by paclitaxel resulted in synergism or antagonism 
in A172, PA-1, and H460 cells. Paclitaxel followed by TQ resulted in antagonism or 
synergism in these cells. These results demonstrate that TQ has a potential as an anti-
neoplastic agent and may affect p53 levels. 
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Chapter One 
 
Introduction 
 
In normal tissues, homeostasis is maintained because of tightly controlled balances 
between cell proliferation and cell death. A disruption in this balance can lead to 
uncontrollable cell growth, which is frequently characterized by the loss of ability to 
undergo apoptosis, and cellular growth spreads without restraint. This type of cell 
behavior characterizes a group of diseases commonly referred to as cancer (American 
Cancer Society). 
 
Cancer is a genetic disease that can result from both internal factors such as hormones, 
inherited mutations, or immune conditions or from external factors such as diet, 
tobacco, radiation, chemical exposure, or infectious organisms to name a few. Typically 
chemical carcinogenesis requires six or seven mutagenic events to occur over twenty to 
forty years (Cross, et al. 1991). This process is generally described to occur in four 
distinct steps: initiation, promotion, malignant conversion, and tumor progression. The 
initial step, initiation, results from irreversible DNA damage. The selective clonal 
expansion of initiated cells comprises tumor promotion. The third step, malignant 
conversion is the stage at which preneoplastic cells are transformed into cells that 
express the malignant phenotype. Lastly tumor progression is the stage in which 
malignant cells are expressed and they tend to acquire more aggressive characteristics.  
 
Cancers can arise almost anywhere in the body. They are initially characterized as 
carcinomas, sarcomas, lymphomas, and leukemias. Carcinomas, the most common 
type of cancer originates from the epithelial cells that cover internal and external body 
surfaces. Breast cancer is the most frequent type of carcinoma diagnosed in the United 
States. The second types of cancer, sarcomas, arise from cells found supporting the 
tissues of the body such as fat, muscle, cartilage, and bone cells. Cancers, which 
originate in the lymph nodes and tissues of the body’s immune system are called 
lymphomas. The fourth type of cancer, known as leukemia, is a cancer of the immature 
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blood cells, which grow in the bone marrow and accumulate in large numbers in the 
blood stream (National Cancer Institute). 
 
Today, cancer is the second leading cause of the death in the United States (following 
heart disease) causing one out of every two deaths in males and one in three deaths in 
females. On a worldwide scale, cancer causes seven million deaths per year (World 
Health Organization). While there are methods for treating cancer that have been 
shown to improve the quality of life of cancer patients, including, chemotherapy, 
surgery, radiation, immunotherapy, and hormones, the improvement in mortality rates 
has been only slight. It is estimated that by the year 2020 there will be twenty million 
new cancer patients per year (American Cancer Society). This data suggests that 
cancer prevalence and incidence is on the rise. New modalities of treatments must be 
discovered which have either the ability to prevent or to destroy existing cancers.   
 
A drug discovery effort to identify a compound, which will provide preventative and/or 
therapeutic treatment, is essential. Over the last millennia herbal medicines have been 
used for the successful prevention and treatment of numerous diseases. Recently, 
herbal medication has also been successfully demonstrated to have anti-neoplastic 
potential and is the source of many chemotherapeutic agents (paclitaxel, vincristine, 
etc). Nigella sativa is a herb that shows encouraging chemopreventive as well as 
chemotherapeutic properties.  
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Chapter Two 
 
Nigella Sativa  
 
Historical Overview 
Black Seed, Black Cumin, Kalunji, Nutmeg Flower, Kalajira, and Roman Coriander are 
all commonly used names for the herbaceous plant, Nigella sativa L. This plant is widely 
distributed, belonging to the botanical family Ranunculaceae. The genus Nigella is 
native to the Mediterranean region and Western Asia, the name being derived from the 
Latin word niger, meaning black, in reference to the color of the seeds (United States 
Department of Agriculture). 
 
Nigella sativa has an erect 30 cm branched stem. The leaves consist of 2-3 cm 
segments, linear to oblong-lanceolate in shape. The flowers are 3.5-4.5 cm in diameter, 
and are white tinged blue, without involucres (Fig 2.1). The fruits are inflated follicles, 3-
7 in number, fused to the base of the outspread styles, forming a capsule containing the 
seeds (Hukley 1992). A more extensive description of Nigella sativa can be found in 
Tutin et al. (1964), Rechinger (1964), and Davis et al. (1965).  
 
Figure 2.1: Nigella Sativa flower and seeds 
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Nigella sativa has an extensive history going back thousands of years. It was referred to 
by the prophet Mohammed of Islam as having healing powers for every illness except 
death (Khan, 1976). According to Birdwood, Black Seed is the "Black Cumin" mentioned 
in the Bible, the "Melanthion" of Hippocrates and Dioscorides, and is the Gith of Pliny ( 
Atta-ur-Rahman et al. 1985a). On the Indian subcontinent, Black Seed has been used 
for hundreds of years as a natural remedy for many health conditions and diseases.  
 
Nigella sativa was first botanically described and characterized by Linnaeus in 1753 
(Abou-Basha et al. 1995). The seed has been used as a spice in cooking, and as a 
preservative for cheese products (El-Sayed et al. 1994). Raw seeds, seed oil, or seed 
extract have been used alone or in combination with other incrediants, as a traditional 
medicine in the treatment of various health conditions, such as eczema, cough, 
headache, diabetes, asthma, infection, and hypertension. 
 
In recent years, the seeds of Nigella sativa have been subjected to a growing number of 
phytochemical and pharmacological investigations. The chemical composition of the 
seed has been determined using a variety of analytical and spectroscopic techniques 
(Houghton et al. 1995, Aboul-Enein and Abou-Basha, 1995, Abou-Basha et al. 1995). 
Also, pharmacological activities of seed extracts have been documented, including 
activities against human and animal diseases, and against pests (Kumar, 1989; 
Schweig, 1999; Khan, 1999).  
 
Nigella sativa’s potential role in cancer therapy 
In vitro studies 
Salomi et al. (1992) studied the antitumor activity of a methanolic extract of Nigella 
sativa seed against different types of cancer cells in vitro, and demonstrated a 50% 
cytotoxicity of this extract against Ehrlich Ascites Carcinoma, Dalton’s Lymphoma 
Ascites, and Sarcoma-180 cells at concentrations of 1.5, 3, 1.5 µg/ml, respectively, with 
little toxicity against lymphocytes. Cell growth of KB (human epidermal carcinoma of the 
mouth) cells was also inhibited (approximately 60%) by the active principle of Nigella 
sativa at a concentration of 0.5 µg/ml, while K-562 (human erythroleukemic) cells 
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resumed growth at near control values on days two and three. Tritiated thymidine 
incorporation studies indicated that the action of the active principle was possibly at the 
DNA level.  
 
In vivo studies 
Salomi et al. (1991) found that topical application of a methanolic extract of Nigella 
sativa inhibited two-stage initiation/promotion of skin carcinogenesis in mice. The same 
group also demonstrated that an injection (intraperitoneal) of the methanolic extract of 
Nigella sativa reduced the number of soft tissue sarcomas formed in the mice induced 
by an initiator (33% treated versus 100% controls).   
 
Salomi et al. (1992) also studied the antitumor activity of a methanolic extract of the 
Nigella sativa seed against Ehrlich Ascites Carcinoma in vivo and demonstrated that the 
development of malignancy was completely inhibited at a dose of 2 mg/mouse per day 
for 10 days.  
 
Abdel-Salam et al. (1992) also treated mice having Ehrlich Ascites Carcinoma with a 
single intraperitoneal injection of Nigella sativa extract (160 mg/kg body weight). It was 
found that the lifespan was significantly increased with 37.5% of the treated rats living 
one month and 25.0% surviving two months. All rats, which did not receive Nigella 
sativa, died by day fourteen. It was also determined that no detectable side effects 
resulted at the administered dose; such as increases in the levels of blood glucose, 
cholesterol aspartate aminotransferase (GOT), and  serum alanine aminotransferase 
(GPT), total proteins, albumin; as well as, liver RNA and DNA. 
 
In a study performed by Mabrouk et al. (2002) the protective effect of Nigella sativa 
seeds on oxidative stress and carcinogenesis induced by methylnitrosourea (MNU) was 
demonstrated in vivo. Rats were injected with a single dose of MNU (50 mg/kg, i.v.) and 
then treated with 0.2 grams of Nigella sativa grains orally. The authors found that the 
oral administration of Nigella sativa grains reduced MNU-induced oxidative stress and 
tumorogenesis by 80%, as compared to the control group.  It also lowered serum 
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Malondealdehyde (MDA) and nitric oxide (NO) levels further demonstrating that Nigella 
sativa has a protective effect against MNU-induced oxidative stress and carcinogenesis. 
 
Pharmacology 
 Hailat et al. (1995) determined the effect of the volatile oil from Nigella sativa seeds on 
Jurkart T cell leukemia polypeptides and found that the volatile oil changed protein 
expression. They concluded that this effect could reflect a role in its biological activity, 
perhaps, through post-translational modification.  
 
In a later study, Medenica et al. (1997) suggested that a Nigella sativa seed extract may 
have strong antitumor activity. The investigators found that the seed extract inhibits 
cancer and endothelial cell progression through the cell cycle, decreases the production 
of the angiogenic protein-fibroblastic growth factor (FGF), and inhibits endothelial cell 
growth factor.. Seed extract was shown to suppress FGF-2, which is commonly present 
in aggressive breast cancers.  
 
Tumor growth angiogenesis is dependent on neo-vascularization a crucial determinant 
of the metastatic potential of the tumor. Formed vessels in tumors are hyperpermeable 
to plasma protein due to gaps in the endothelial lining. These vascular abnormalities 
can facilitate entry of the tumor cells into the circulation. The authors also studied breast 
cancer, prostate cancer and melanoma cells for acidic fibroblast growth factor, which 
were suppressed by the extract. An attempt was made to recapitulate early angiogenic 
evidence in vitro by developing a model of endothelial growth migration and 
extracellular matrix interaction. The in vitro assay revealed that stimulated endothelial 
cells could produce degradative proteinase and invade the extracellular matrix similar to 
tumor cells. Moreover, this model system indicated that a fine-tuned balance between 
proteinase and proteinase inhibitor regulates vascular morphogenesis and invasion. 
Migrating endothelial cells produce Type 4 collagenase (a member of the matrix 
metalloproteinase family) and serine proteinase. The authors further demonstrated that 
specific inhibitors of Type 4 collagenase, general metalloproteinase inhibitors and serine 
proteinase inhibitors blocked endothelial cell invasion of the extracellular matrix. These 
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inhibitors blocked tumor cell invasion in the same assay. The extract was compared 
with these factors and shown to have the same action. The endothelial cells in culture 
reverted to a non-angiogenic state when the angiogenic stimulus was neutralized by the 
extract. The authors concluded that the activity of the seed extract blocked the tumor 
growth and dissemination in metastasis and has remarkable promise for clinical use.  
 
Unfortunately, only a few studies have related certain biological activities to specific 
chemical entities in blackseed.  
 
One particular chemical entity found in Nigella sativa is thymoquinone. Mahfouz and El-
Dakhakhny (1960a) reported the identification of “a polymer of the active principle” and 
named it nigellone: This component was separated from the essential oil of the seed. 
Three years later, El-Dakhakhny (1963) isolated a crystalline substance from the 
essential oil, which he identified as thymoquinone (Fig 2.2). Ghosesh et al., (1999) 
demonstrated that this component is the major constituent of Nigella sativa. Since its 
discovery it has been demonstrated to exhibit anti-microbial, antioxidant, anti-
histaminergic, anti-inflammatory, anti-diabetic, analgesic, anti-pyretic, and anti-
neoplastic activity. It is the anti-neoplastic activity, which has recently gained a 
significant amount of attention. 
 
FIGURE 2.2: Chemical structure of Thymoquinone 
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Thymoquinone’s Potential Role in Cancer Therapy  
In vitro toxicity 
Worthen et al. (1997, 1999) investigated the in vitro anti-tumor activity of purified 
components of Nigella sativa seeds. Thymoquinone was assayed in vitro for its 
cytotoxicity against several human tumor cell lines. Thymoquinone was cytotoxic for all 
the cell lines tested [IC50's 78-393 µM]. Both the parental cell lines and their 
corresponding MDR (multi-drug resistant) variants (which were over 10 times more 
resistant to the standard antineoplastic agents doxorubicin and etoposide, as compared 
to their respective parental controls) were equally sensitive to thymoquinone. The 
inclusion of the competitive MDR modulator quinine in the assay reversed MDR DX-5 
cell resistance to doxorubicin and etoposide by 6 to 16 times, but had no effect on the 
cytotoxicity of thymoquinone. Quinine also reduced MDR DX-5 cell accumulation of the 
P-glycoprotein substrate 3H-paclitaxel in a dose-dependent manner. However, 
thymoquinone did not significantly alter cellular accumulation of 3H-paclitaxel. The 
inclusion of 0.5% (w/v) of the radical scavenger DMSO in the assay reduced the 
cytotoxicity of doxorubicin by as much as 39%, but did not affect that of thymoquinone. 
These studies suggest that thymoquinone is cytotoxic for several types of human tumor 
cells, may not be a P-glycoprotein substrate, and that radical generation may not be 
critical to its cytotoxic activity. The investigators concluded that thymoquinone may 
serve as a useful anticancer drug and as a lead compound for the development of novel 
agents designed for the treatment of MDR tumors resistant to standard antineoplastics. 
 
Chemoprotection 
Badary et al. (1999) examined the effect of thymoquinone on Ifosfamide-induced 
Fanconi (IFO) syndrome and its antitumor activity in rats and mice.  Ifosfamide was 
injected (50 mg/kg/day, i.p.) for five days to induce Fanconi syndrome, which is 
characterized by renal wasting of glucose, electrolytes, and organic acids.  It also 
resulted in elevated levels of serum creatinine and urea. Thymoquinone was 
administered in drinking water (0.5 mg/kg/day) for five days before and during 
Ifosfamide treatment. This administration significantly reduced the elevated serum urea 
and creatinine, prevented the decrease in serum phosphate and albumin, reduced the 
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fractional and total excretion of Na+, K+, PO4-3, glucose, and organic acids as compared 
to ifosfamide only  treated rats. The creatinine clearance rate was also significantly 
increased. As in the 1997 study by Badary et al., the authors found that IFO and 
thymoquinone when given to EAC bearing mice resulted in decreased mortality and less 
body weight loss as compared to IFO treated mice. 
 
Tumor initiation and prevention 
Badary et al (1999) further characterized the affect of thymoquinone on benzo-(a)- 
pyrene-induced (BP) forestomach tumors in mice.  BP was administered orally (1mg), 
twice weekly for four weeks. Thymoquinone (100mg/ml) was administered in drinking 
water one week before, during, and after BP treatment until the end of the experiment. 
The authors found that thymoquinone inhibited BP-induced forestomach tumor 
incidence and multiplicity by 70% and 67%, respectively. Thymoquinone alone showed 
a significant induction of the enzyme activities of hepatic glutathione-s-transferase and 
DT-diaphorase. This data indicates that thymoquinone acts as a powerful 
chemoprotective agent against BP-induced forestomach tumors in mice. The authors 
speculate that the possible modes of action of thymoquinone may be through its anti-
inflammatory and antioxidant activities. 
 
Badary et al (2000) also examined the affects of thymoquinone on 20-
methylcholanthrene-induced fibrosarcoma (MC) tumorogenesis. MC was injected (200 
µg/kg, subcutaneous). Administration of thymoquinone inhibited the tumor incidence 
and tumor burden by 43% and 34%, respectively compared to the group receiving MC 
alone. Again, thymoquinone showed a significant induction of the enzyme activities of 
hepatic GST and DT-diaphorase. These last three studies by Badary et al have shown 
that thymoquinone has promise as a chemoprotective agent.  
 
Pharmacology 
Most recently Shoeib et al (2002) demonstrated the in vitro inhibition of growth and 
induction of apoptosis in cancer cell lines by thymoquinone. Thymoquinone cytotoxicity 
was investigated using canine osteosarcoma (COS31), its cisplatin-resistant variant 
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(COS31/rCDDP), human breast adenocarcinoma (MCF-7), and human ovarian 
adenocarcinoma (MDCK) cell lines. All cell lines were sensitive to thymoquinone.  
Mechanistic studies showed that 25µM of thymoquinone induced apoptosis of COS31 
cells six hours after treatment and decreased the number of cells in S-phase while 
increasing the number of cells in G1 phase, indicating cell cycle arrest at G(1). The 
authors believe that thymoquinone exerts its effects by inducing apoptosis and cell cycle 
arrest. 
 
From the above discussion it is apparent that the curative and preventative properties of 
Nigella sativa are significant. To advance the knowledge of this plant and its constituent, 
thymoquinone, led to the studies discussed in this thesis. However, in order for 
meaningful data to be collected it is essential to have basic knowledge of the cell cycle 
and proteins affected by cancer. This knowledge will allow for appropriate experiments 
to be designed and end points to be monitored.  
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Chapter Three 
Cell Cycle Control and Protein Expression in Cancer 
 
Normal Cell Cycle and Protein Expression 
In order for healthy cells to maintain a balance between cell production and cell death, 
intracellular and extracellular signals must be integrated in a set order.  The cell cycle 
can be broken down into four phases. It is during these phases that a mammalian cell 
will replicate the entire genome and divide into genetically identical daughter cells. 
During the first phase, G(1) (gap 1), biochemical changes take place within the cell 
which prepare it for entry into the next phase. This next phase is called S phase 
(synthesis), at this time new DNA is synthesized and the cell creates an entire copy of 
its genetic material. The third phase, G(2) (gap 2), is a preparatory phase leading to 
entry into the last phase, M phase (mitosis). During M phase DNA condensed into 
chromosomes. These chromosomes are segregated into two daughter cells where each 
receive a full copy of the genetic material. A fifth phase does exist called G(0). Cells at 
G(1) can enter into G(0) if environmental growth factors are not right for the cell to 
proceed to S phase. Entry into S phase is irreversible (Rosenberg,  2001). 
 
Figure 3.1: Cartoon illustration of the normal cell cycle 
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In the cell cycle, there are two interacting components: (a) the “mechanical” component,  
which refers to DNA replication, mitosis and cytokinesis; and (b) the “regulatory” 
components which refer to events in G(1) that control entry into the S phase and those 
in G(2) that regulate entry into mitosis . The proper progression of the cell cycle events 
depends primarily upon accurate chromosome replication and segregation, which is 
achieved by assuring that each step, is completed before the next one begins. Damage 
to these mechanisms, which results in failure to control cell cycle events, can cause 
alterations and mutations that may cause cell death or cancer. (Pusztai, 1996). 
 
In order to avoid irreversible mistakes, initiation of any event in the cell cycle is 
dependent upon completion of earlier events. For this ordered dependency to be 
enforced the cell has developed control mechanism called checkpoints. These cell cycle 
checkpoints are regulated by components of the cells cycle machinery. In cases where 
nuclear DNA has been damaged normal cells cease to progress through the cell cycle 
at one of two points: either prior to entry into S-phase or prior to entry into mitosis. 
Arrest at these phases will limit propagation of genetic mutations to daughter cells by 
allotting time for DNA repair or initiation of cell death, however loss of a checkpoint can 
lead to a number of abnormalities including cancer (Rosenberg,  2001.) 
 
Cell-cycle progression is governed by key regulatory proteins, which are controlled by 
posttranslational modification. Posttranslational modifications function to alter the 
stability and increase the protolytic degradation of these proteins (Blagosklonny,  2001). 
 
A detailed discussion of the cell cycle transitions and the proteins that control them is 
presented below. 
 
G(1)-S transition in cells and cell cycle checkpoints 
In order for cells to complete the G(1) to S phase transition extracellular growth factors 
must be present for the cells to pass the first restriction point. This restriction point is 
defined as a point in late G(1) at which growth factors are no longer required. If 
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adequate growth factors are not present the cell will enter G(0) (Pardee,  1974). During 
the transition past this initial restriction point a series of biochemical events occur. First 
the protein complex cyclin D/cdk 4 is activated. This activated complex will 
hyperphosphorylate the protein RB. Upon hyperphosphorylation, RB will disengage 
from its partner E2F-1. The physical interaction of RB with E2F-1 blocks gene activation 
by E2F-1, a necessary step for cell cycle progression. Thus, upon hyperphosphorylation 
of RB, the E2F-1 gene is released and can now mediate gene activation and 
progression to the S phase (Nevins,  1998). 
 
DNA damage at G(1) will result in cell cycle arrest due to the tumor suppressor gene, 
p53. Following DNA damage p53 levels and activity are increased. An increase in p53 
can lead to an increase in the level of p21 (WAF1/CIP1) which serves to inhibit the 
activity of the cyclin/cdk complexes. Inhibition of cyclin/cdk will prevent 
hyperphosphorylation of RB thus preventing E2F-1 release which has previously been 
shown to drive the G(1) - S transition. p53 also functions as a cell cycle checkpoint 
protein by driving apoptosis following DNA damage (Levine,  1997). 
 
S-phase 
During S-phase a complete copy of the genetic material must be generated. For this to 
occur, DNA synthesis must begin at a defined location in the genome or an origin of 
replication (ORC).  For DNA synthesis to be initiated and progress multiple proteins 
must bind to the DNA to aid in this process. These proteins are called the origin of 
replication complex (ORC).  At different times, this phase of the cell cycle, two ORCs 
can be observed, a pre-ORC and a post-ORC.  The pre-ORC binds to and prepares the 
DNA for replication at the end of G (1) but does not allow for replication to begin. Upon 
entry into S phase the post-ORC complex forms and allows the cell to proceed with 
DNA synthesis. Regulation of the pre-ORC and post-ORC is likely responsible for the 
mechanism by which cells cannot re-replicate DNA during the S phase (Rosenberg, 
2001). 
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While little is known about the DNA-damage induced checkpoint controls during this 
phase of the cell cycle, a recently identified gene, ATM, a cytoplasmic protein kinase, is 
known to phosphorylate certain proteins such as p53 which are involved in DNA 
damage repair (Banin et al.1998). 
 
M Phase 
Following the S phase the cell enters G(2) and prepares for mitosis. During mitosis the 
duplicated genome is segregated into two daughter cells. It is crucial that M phase be 
successfully completed because errors in this process can lead to alterations in the 
genetic material such as loss of a chromosome (Hartwell, and Weinert, 1989). The M 
phase is also irreversible.  
 
There are several stages within M-phase. During the first stage cells enter mitosis; this 
is controlled to prevent the segregation of chromosomes that have not finished DNA 
synthesis. During the second stage structural changes occur that prepare the sister 
chromatids to separate. The next stage at which the sister chromatids separate is an 
important checkpoint for the cell because this process is not easily reversed. During the 
last stage the chromosomes decondense, reform their nuclear envelope, and the cells 
undergo cytokinesis to complete the cell cycle (Rosenberg, 2001). 
 
There are three levels of regulation during mitosis. Activation of the protein complex 
cyclin B/cdk1 is the first crucial regulatory mechanism, which governs whether cells 
enter mitosis. Cyclin B levels increase during late S and G(2) phase. The newly 
synthesized cyclin B will bind to dephosphorylated cdk1 (Blow, J., 1989). This is then 
activated by phosphorylation from a cdk-activating complex and localizes to the 
nucleus. The second level of regulation involves a family of kinases known as Polo-Like 
Kinases (PLKs). These are localized to spindle pole bodies, kinetichores and the 
spindle mid-zone at different stages in mitosis, thus playing a role in spindle apparatus 
assembly, paring of the sister chromatids and separation. PLKs are also involved in 
activation of the APC/cyclosome. The APC cyclosome serves as the third regulatory 
mechanism. The APC cyclosome causes destruction of certain proteins by ubiquination. 
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Thus the APC cyclosome controls the entry into, transition through, and exit from 
mitosis (Rosenberg, 2001). 
 
During mitosis a checkpoint exists to prevent the metaphase to anaphase transition until 
sister chromatid pairs are aligned and attached at the spindle apparatus. This 
checkpoint is also thought to be controlled by the p53 protein. 
 
Cancer Development 
The molecular mechanisms that control cellular proliferation include both positive and 
negative regulators. Many regulatory proteins involved in the stimulation of proliferation, 
such as growth factors, growth factor receptors or proteins that participate in signal 
transduction, have been identified. 
 
Cancer develops when the delicate balance between cell formation and cell death is 
disrupted. Dysregulation of cell cycle control is a phenomenon common to all forms of 
cancer. This can occur in one of two ways: lack of a cellular death program in response 
to stress, or lack of appropriate control responses to signals which normally cause the 
cells to halt progression through the cell cycle.  Following discoveries made in the 
1970s and 1980s, it has become clear that tumor cells results from too many cell cycle 
accelerators (oncogenes) and too few cell cycle decelerators (tumor suppressor genes 
e.g. p53) (Cross, 1991). This model has since been revised to recognize the roles of cell 
death controls. It now appears that tumor formation also results from decreased pro-
apoptotic signals (p53), and increased anti-apoptotic signals (BCL-2) (Jacobson et al. 
1993). 
 
There are many known oncogenes such as c-SIS, an abnormally activated growth 
factor, and RAS, an intercellular signaling molecule. While these oncogenes do exist in 
some types of cancer it appears that the most influential factor leading to cancer is the 
loss of the tumor suppressor gene p53 (Rosenberg, 2001). p53 directly influences cell 
cycle machinery by, as previously mentioned, inducing p21 (WAF1/CIP1) to inhibit 
activation of cdk. Cdk will not be able to phosphorylate RB and thus E2F-1 will not be 
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able to mediate gene activation. If p53 function is lost both, inappropriate progressions 
through the cell cycle after DNA damage and survival of cells, which might have been 
destined to die, will occur. It is not surprising that p53 is the most commonly mutated 
gene and that an estimated 50% of human malignant tumors have mutated p53 (Soussi,  
2000). 
 
In conclusion, the cell cycle consists of a complex set of sequential, well coordinated 
specific events that result in cell division, and thus is central to proliferative diseases 
such as cancer. The genes which regulate the cell cycle, its checkpoints, and the 
factors which control it, are essential for the initiation, promotion, and progression of 
cancer. 
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Chapter Four 
 
p53: the Core of DNA damage Pathways 
 
The p53 tumor suppressor protein is a transcription factor with “sensor” functions 
integrating signals from the external and internal environment. The p53 tumor 
suppressor protein is a 53kDa nuclear phosphoprotein that can function as a sequence 
specific transcriptional activator and nonspecific transcriptional repressor. The p53 
protein is also involved in cellular differentiation, DNA repair, senescence, and 
angiogenesis. Wild type p53 and intact signaling pathways minimize the formation of 
cancer, which is consistent with a high tumor incidence observed in p53-deficient mice 
(Choi, et al., 1999). It is estimated that approximately one half of human cancer cells 
contain a mutation of p53.  The increased predisposition to tumor development in the 
absence of p53 is due to the accumulation of genetic alterations in cells and the failure 
to eliminate these defective cells (Soussi, 2000). Thus, p53 is a major DNA damage 
checkpoint gene and is clearly required for a complete DNA damage response. 
 
Wild type p53 is a labile protein with a short half life (Linzer et al., 1979). Accumulation 
and activation of this protein can be triggered by a variety of stress signals including 
DNA damage, hypoxia, nuclear deprivation, viral infection, heat shock, and mitogenic or 
oncogenic activation. The specific activity of p53 is further enhanced by 
posttranslational modifications and by a variety of positive and negative regulators 
(Bennett, 1998). Activated p53 elicits cellular responses that ultimately lead to growth 
arrest and/or apoptosis.  
 
Regulation of p53 
The p53 protein is subject to tight regulation at multiple levels. This is achieved by a 
variety of positive and negative regulators often creating feedback loops. Three major 
levels of regulation are recognized; protein stability, protein activity, and sub-cellular 
distribution (Blagosklonny, 2001).  These are described in detail below. 
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Mdm-2 negative regulatory feedback loop 
The major negative regulator of p53 is the Mdm-2 proto-oncogene. Mdm-2 is a 
transcription factor induced by p53. Thus, p53 causes its own destruction through a 
negative feedback loop (Momand, 1997). This feedback loop leads to variations in the 
expression of both proteins following DNA damage. Over expression of Mdm-2 can 
result in inactivation of p53 without further mutation and similarly loss of Mdm-2 is 
sufficient to induce p53 mediated apoptosis. Therefore, Mdm-2 is critical in keeping p53 
in check and hence is referred to as “the master regulator “(Momand et al. 2000). 
 
Mdm-2 and p53 proteasomal degradation 
Haupt et al. (1997) demonstrated that Mdm-2 promotes p53 degradation through the 
ubiquitin proteasome system. Mdm-2 promotes p53 for degradation by acting as an E3 
ubiquitin ligase. The exact mechanism of proteasomal degradation is not completely 
understood. It is possible that additional proteins may be involved in ubiquination of p53 
by Mdm-2 in vivo. A possible candidate is Janus Kinase (JNK) which binds p53 and has 
been implicated in the ubiquination of p53 in unstressed cells (Fuchs et al.1998). 
 
Mdm-2 inhibits p53 activity 
Mdm-2 binds the trans-activation domain of p53 in a region important for the interaction 
of p53 with the components of the transcription machinery, such as TATA-binding 
protein (TBP)  and associated factors (TAFs) and with its transcriptional coactivator 
p300. These observations prompted the construction of a model, called a “masking 
model,” which hypothesizes that the binding of Mdm-2 to p53 conceals its 
transactivation domain thus inactivating it (Oliner et al. 1993). In spite of all of the 
studies done on Mdm-2 and p53 it is difficult to distinguish between the effects of Mdm-
2 on p53 stability from its effect on p53 activity. A schematic diagram illustrating the 
various domains present in p53 including the Mdm-2 binding domain is shown in fig. 
4.1. 
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Figure 4.1 Illustration of the various domains present on the p53 gene 
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Involvement of interacting proteins 
The majority of the positive regulators of p53 can be classified into two groups: (a) 
proteins that activate and stabilize p53 by neutralizing the inhibitory effects of Mdm-2 
and (b) proteins that bind the C-terminus of p53 and activate it by protecting p53 from 
the inhibitory effects of this region, this is illustrated in fig. 4.1. Thus, p53 is regulated by 
a variety of proteins and a variety of stimuli (Blagosklonny, 2001). Figure 4.2 is a 
composite illustration showing a few of the regulatory interactions of p53 and its 
subcellular distribution. 
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Figure 4.2: A possible model for p53 regulation 
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p53-mediated growth regulation 
Once activated p53 triggers either growth arrest or apoptosis. p53 is crucial for the 
induction of growth arrest by numerous stress signals.  
 
p53 mediated-cell cycle arrest in G(1) phase 
The p53 target gene which is the key factor in G(1) arrest is p21 (the WAF1/Cip1). p21 
inhibits different complexes of cyclin/cdk which sequentially phosphorylate the Rb 
protein, and as a result reduce the S-phase promoting E2F-1 transcription factor. p53 
also promotes G(1) arrest by directly inhibiting the activity of  cdk-activating kinase 
(CAK) which activates cyclin A/cdk2 by phosphorylation. Binding of p53 to CAK results 
in an increase in G(1) arrest. In addition p53 may activate Rb via PC3 (TIS21, BTG2), a 
newly identified p53 target gene. The PC3 gene product promotes accumulation of 
hyperphosphorylated Rb by reducing cyclin D1 protein levels and thereby inhibiting 
CDK4 activity (Brehm, et al. 1998) Figure 4.3 summarizes these pathways. 
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Figure 4.3: Role of p53 in G1 arrest 
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p53 mediated G(2) arrest 
Activation of p53 can promote and maintain G(2) arrest. This depends on functional Rb 
protein and is mediated by several target genes. The p53 protein and its target genes 
effectively inhibit the cyclin B1/Cdc2 activity, which is essential for cells to enter mitosis. 
p21 inhibits the activity of the cyclin B1/Cdc 2 complex. The other important protein 
activated by p53 is GADD45. This protein binds Cdc2 and disrupts its ability to complex 
cyclin B1 and mediated G(2) arrest. The other protein activated by p53 is 14-3-3-σ. The 
14-3-3-σ protein sequesters and inhibits the phosphorylated form of Cdc25c (Hermeking  
et al. 1997.) 14-3-3-σ also sequesters Cdc2 in the cytoplasm and prevents it from 
translocating into the nucleus in the late G(2) phase. The effects of the above proteins 
are further compounded by the transcriptional repression of Cdc2 and cyclin B1 by p53. 
Figure 4.4 summarizes these pathways. 
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Figure 4.4: Role of p53 in G2 arrest 
 
 
 
 
p53 and Mitotic Spindle Checkpoint 
Loss of p53 function leads to genomic instability, abnormal centrosome duplication, and 
formation of aneuploid and polypoid cells. This suggests that p53 plays a role in the 
control of centrosome duplication and normal chromosomal segregation. The exact 
mechanism is not known but may involve a variety of proteins. A cooperative role may 
exist between p53 and its interacting protein BRCA-1 in regulating chromosomal 
segregation. Both the proteins associate with centrosomes in mitosis and bind to 
gamma tubulin; however the importance of the interactions are unknown (Meek, 2000). 
 
p53 mediated apoptosis 
p53’s role in modulating the apoptotic response likely plays an important role in p53’s 
tumor suppressor activity. p53 is known to trigger apoptosis following the appropriate 
signals. The mechanistic pathways connecting p53 to the apoptotic death machinery 
 23
have remained illusive. No single mediator of p53’s apoptotic activity has emerged. In 
fact, a variety of experimental systems have suggested that p53 may fundamentally 
utilize at least two apoptotic pathways. The two pathways leading to apoptosis are the 
death receptor and the mitochondrial pathways. 
 
p53 may mediate apoptosis in a transcription dependent or transcriptional independent 
pathway.  The transcription dependent pathway of apoptosis suggests that p53 
activates death promoting genes such as BAX, CD95/Fas/Apo1, the PIG genes 
involved in redox regulation, and TNF-receptor family of genes containing death 
domains (Miyashita et al., 1995 and Zhan et al., 1994).  In spite of the growing list of 
p53 target genes involved in apoptosis the precise mechanism by which activation of 
these genes lead to apoptosis is not clear. 
 
Information has emerged from studies that suggest, p53 may trigger apoptosis without 
the apparent need for transcriptional activity (Chao et al., 2000, and Attardi et al., 1996). 
The original data supporting this possibility came from the observation that p53’s 
apoptotic activity was resistant to actinomycin D and cyclohexamide treatment. p53 has 
a proline rich region which contains several SH3 binding motifs (PXXP) and displays 
SH3 binding activity. This proline rich domain is important for p53’s apoptotic function 
(Walker et al., 1996). A mutation in this region does not affect the ability p53 to arrest 
the cell cycle but prevents it from triggering apoptosis. This region perhaps serves as a 
regulatory domain for p53 mediated transcription independent apoptosis.  
The possible pathways are illustrated in Figure 4.5. 
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Figure 4.5: Transcription dependent and independent pathways of apoptosis by 
p53 
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It appears that p53 is a major determinant in cancer development, and thus a drug 
which could target this protein and promote its up-regulation or block its down regulation 
would be of great value in cancer treatment.  
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Chapter Five 
Hypothesis and Aim of Study 
 
With the promising results from the Nigella sativa and thymoquinone studies and the 
knowledge of how cancer cells differ from normal cells, as well as, insight into the role of 
p53 in the cancer development process, it was possible to develop a hypothesis, ask 
some novel questions, and devise a set of experiments to answer these.  The goal of 
the following research was to further monitor and evaluate thymoquinone’s cytotoxic 
effects in common human tumors, determine if these effects are related to p53 status, 
determine the effect on the cell cycle,  and evaluate the mechanism of cell death 
(apoptotic versus necrotic).  
 
Hypothesis: Thymoquinone functions as a cytotoxic agent through the 
upregulation of the p53 protein. 
 
Specific Aim 1:  To assess cytotoxicity of thymoquinone in common human 
tumor cell lines with varying p53 expression levels. 
The first step in the investigation was to determine the cytotoxicity of thymoquinone in 
three human ovarian cancer cell-lines (PA-1, SKOV-3 and CAOV-3). These cell lines 
were chosen because of their varying p53 status. With these experiments it was 
possible to assess if varying p53 expression played a role in thymoquinone’s ability to 
kill these cells.  
 
Specific Aim 2: To determine the sensitivity of common tumor cell lines with wild-
type p53 to thymoquinone, and determine the effect of thymoquinone on p53 
expression in these cell lines. 
If p53 does play a role in thymoquinone’s ability to manifest as an anti-neoplastic agent 
then the next step is to determine if cell-lines with wild-type p53 are consistently 
susceptible to the anti-neoplastic activity of thymoquinone. The cell-lines chosen were 
PA-1, A172, H460, and A549. All of these cell lines posses a wild-type p53 protein. 
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Experiments would be performed to determine changes in p53 expression in 
thymoquinone treated compared to untreated cells.  
 
Specific Aim 3: To determine if thymoquinone works in synergy with cell cycle 
non-specific or cell cycle specific agents. 
The next set of experiments was to determine the effect of thymoquinone on the cell 
cycle, when administered in combination with other chemotherapeutic agents. If 
thymoquinone’s cytotoxic function is p53 dependent than this could play a role in 
determining the drug regime for cancer therapy. The drugs chosen for these 
combination studies were the cell-cycle specific agent, paclitaxel, and the non cell-cycle 
specific agent, cisplatin. The cell-lines used for these studies were PA-1, A172, and H-
460. 
 
Specific Aim 4: To determine the effect of thymoquinone on the cell cycle. 
To further elucidate the effect of thymoquinone on the cell cycle, flow-cytometry 
analyses were conducted. The aim of this experiment was two-fold; to assess if 
thymoquinone affected the cell lines at a particular phase in the cell cycle as would be 
predicted by p53 upregulation, and to analyze if thymoquinone caused its cytotoxic 
effect via necrosis or apoptosis. 
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Chapter Six 
 
Materials and Methods 
 
Media and Chemicals 
The established human ovarian cancer cell lines PA-1, SKOV-3, and CAOV-3, the 
human glioblastoma cell line A172, and the non-small cell lung cancer cell lines A549 
and H460 were used in these experiments. All cells were obtained from American Type 
Cell Collection (Manassas, VA, USA). The cells were cultured in Dulbecco’s Modified 
Eagle Media (DMEM) (Gibco BRL, Gaithersburg, MD, USA). The following supplements 
were added to the media 10% fetal bovine serum (Gibco), 4mM glutamine (Gibco), 
sodium pyruvate (Gibco), and penicillin/streptomycin solution (100ug/ml) (Gibco). The 
PA-1 cells further required a supplement of non-essential amino acids (Gibco). The cells 
were maintained at 37°C in humidified 5% CO2 atmosphere for a minimum of 72 hours 
before each experiment.  
 
Additional Materials included: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS), which was purchased from Promega 
(Madison, WI, USA), and ApoAlert Annexin V-FITC Apoptosis Kit (BD Biosciences Palo 
Alto, CA, USA). Phenazine methosulfate (PMS), ribonuclease A, and propidium Iodide 
were purchased from Sigma-Aldrich (St. Louis, MO, USA).  Primary monoclonal p53 
antibody was obtained from Oncogene (San Diego, CA, USA). The secondary antibody, 
goat anti-mouse, was obtained from Chemicon International, Inc. (Temecula, CA, USA). 
Paclitaxel was purchased from Abbott Laboratories (Chicago, Il, USA) and cisplatin was 
purchased from GensiaSicor Pharmaceuticals (Irvine, CA, USA). Lastly, thymoquinone 
was purchased from Acros Organic (New Jersey, USA).   
 
Preparation of Thymoquinone 
Thymoquinone was reconstituted in methanol at a concentration of 10mg/ml. This stock 
was stored at 4°C in 15ml centrifuge tubes wrapped in aluminum foil to avoid dimer 
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formation. This stock was diluted as needed in DMEM to produce the concentrations to 
be tested. 
 
Cell Proliferation Experiments  
The proceeding colorimetric experiments were analyzed by using KC4 General Data 
Reduction Package Software and the ELx808 Ultra Microplate Reader (BioTek 
instruments, Inc. Winooski, VT, USA). KC4 software is used to quantify data generated 
from the MTS colorimetric assay. The MTS assay calculates the % of live cells using the 
following equation:(sample - blank)/(control - blank). The blank well contains only the 
MTS solution and is subtracted out in order to remove background absorbance. The 
control wells contain untreated cells, while the sample wells represent the treat cells. To 
monitor the effects of concurrent or sequential drug exposure the data obtained from the 
KC4 analysis was further subjected to analysis by Calcusyn (Biosoft ®) software to 
predict additive, synergistic, or antagonistic effects. 
 
24-hour exposure experiments: 
PA-1, and SKOV-3 cells were plated in 96 well plates at a concentration of 1 X 103  
cells/well and CAOV-3 cells were plated in 96 well plates at 5 X 103 cells per well. The 
cells were allowed to adhere overnight before addition of thymoquinone. Thymoquinone 
stock was diluted in media by one-fourth for seven concentrations starting at 28µM for 
PA-1 cells, 320µM for SKOV-3 cells, and 800µM for CAOV-3 cells. The cells were 
exposed to the thymoquinone for 24 hours. Following this exposure the thymoquinone 
was removed and 100µl of media was reapplied to the cells. Cell viability was assessed 
using the MTS assay. 
 
48-hour exposure experiments: 
PA-1, A172, H460 cells were plated in 96 well plates at concentrations of 3 X 103 cells 
per well, and A549 cell were plated at 1 X 103 cells per well. The cells were allowed to 
adhere overnight before addition of thymoquinone. Thymoquinone stock was diluted in 
DMEM (serial dilutions 1:4) to obtain the final concentrations of 28 - 0.0017µM for PA-1 
cells, 448 -1.75µM for A172 and H460 cells, and 256 - 0.0625µM and for A549 cells. 
Each cell line was exposed to seven concentrations within the designated concentration 
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range. These cells were exposed to the thymoquinone for 48 hours. Following this 
exposure the thymoquinone was removed and 100µl of media was reapplied to the 
cells. Cell viability was assessed using the MTS assay. 
 
48-hour exposure followed by 24 hours of recovery in media: 
PA-1, A172, H460 cells were plated in 96 well plates at concentrations of 3 X 103, 3 X 
103 and 2 X 103 cells per well respectively. The cells were allowed to adhere overnight 
before addition of thymoquinone. Thymoquinone stock was diluted in DMEM (serial 
dilutions 1:4) to obtain the final concentrations of 512 – 0.0078µM for PA-1 and 1024 – 
0.015µM for A172 and H460 cells. Each cell line was exposed to seven concentrations 
within the designated concentration range. These cells were exposed to thymoquinone 
for 48 hours. Following this exposure the thymoquinone was removed and 100µl of 
media was reapplied for 24 hours to the cells. Cell viability was then assessed using the 
MTS assay. 
 
120-hour exposure experiments: 
PA-1, A172, H460, and A549 cells were plated in 96 well plates at concentrations of 7.5 
X 102, 5 X 102, 1 X 103, and 5 X102 cells per well, respectively. The cells were allowed 
to adhere overnight before addition of thymoquinone. Thymoquinone stock was diluted 
in DMEM (serial dilutions 1:4) to obtain the final concentrations of 128-0.03125µM for 
PA-1, A172, and A549, and 256- 0.0625µM for H460 cells. Each cell line was exposed 
to seven concentrations within the designated concentration range. After 48 hours of 
exposure the thymoquinone was removed and reapplied in fresh media. Following 
another 48 hours the thymoquinone was again removed and reapplied in fresh media. 
After 24 hours cell viability was monitored using the MTS assay. 
 
P53 quantification by Western Blot Analysis  
Protein extraction 
PA-1, A549, A172, and H460 cells were plated into 100cm Petri dishes at 
concentrations of 1.5 X106 for PA-1, 3X106 for A549, and 2 X 106 for both A172 and 
H460 cells per dish. Thymoquinone was administered for 48 hours at a concentration 
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that resulted in 50% cell death. After 48 hours of exposure protein extracts were 
prepared by washing the cells with PBS and counting them. They were then pelleted 
and suspended in Laemelli Lysis Buffer. The lysis buffer was boiled for five minutes at 
95°C.  The samples were then stored at 4°C for a maximum of six months. A total of 
four thymoquinone treated samples were prepared for H460, A549, and A172, and six 
treated samples were prepared for the PA-1 cells. Control samples were also prepared 
by treating A549 cells with 25nM Paclitaxel which is known to upregulate p53 levels 
(Giannakakou, P., 2001). 
 
Gel loading, transfer, and development 
The protein extracts were loaded onto a 12%  polyacrylamide gel and were subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a Bio-
Rad apparatus. The running time was approximately one hour. The gel was transferred 
to a nitrocellulose membrane for 45 minutes using a Bio-Rad gel transfer apparatus. 
Following the transfer, the nitrocellulose membrane was immersed in blocking buffer 
(5% powdered milk in tris buffer) for one hour. The membrane was then subjected to an 
immunoblotting procedure, which involved adding primary monoclonal antibodies to p53 
and β-actin (concentration of p53 100:1, and actin 5000:1) and incubating for two hours 
at room temperature or overnight at 4°C with slow constant shaking. This was followed 
by three 10-minute washes with tris-buffer prior to a one hour incubation with the 
secondary antibody (goat anti-mouse IgG horse radish peroxidase conjugated). The 
membrane was washed again as above before subjecting the membrane to the 
development procedure. The membrane was developed using the chemilumensent ECL 
system. The membranes were exposed to x-ray film for varying times periods (0.5 to 4 
minutes). Equal protein loading was verified by actin probing. Quantification was 
performed by acquiring an image of the film with a CCD camera (Syngene, Cambridge, 
UK), which allowed densitometry with computer software. (GeneSnap and GeneTool 
software (Syngene, Cambridge, UK)).  The results are normalized to the paclitaxel 
treated A549 positive control before comparisons are made. 
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Combination Drug Therapy Studies (Synergy/Antagonism) 
Concurrent exposure to thymoquinone and cisplatin 
PA-1, A172, H460 cells were plated in 96 well plates at concentrations of 3 X 103 cells 
per well for the PA-1 and A172 and 2 X 103 cells per well for the H460.  The cells were 
allowed to adhere overnight before addition of thymoquinone and cisplatin. Each 96 well 
plate was divided into regions: region one was thymoquinone and cisplatin, region two 
was thymoquinone alone, and region three was cisplatin alone. Thymoquinone and 
cisplatin were added to the 96 well plates in ratios of 4:1, 1:1, and 1:4 on separate 
plates respectively. These ratios were chosen based on the monotherapy studies which 
indicated that thymoquinone was effective at concentrations similar to cisplatin. For PA-
1 cells at a 4:1 ratio (thymoquinone: cisplatin) the concentrations were 28 – 0.0068µM: 
7- 0.0017µM, at a 1:1 ratio the concentrations were 7-0.0017µM: 7-0.0017µM, and at a 
1:4 ratio the concentrations were 7-0.0017µM: 28-0.0068µM. For A172 and H460 at a 
ratio of at 4:1 (thymoquinone: cisplatin) the concentrations were 448 – 7µM: 112- 
1.75µM, at a 1:1 ratio the concentrations were 112-1.75µM: 112-1.75µM, and at a 1:4 
ratio the concentrations were 112-1.75µM: 448- 0.1094µM. Each cell line was exposed 
to seven concentrations within the designated concentration range and these 
concentrations were diluted by one-fourth starting from the top concentration. After 
twenty four hours of exposure to thymoquinone, cisplatin or both, the 96 well plates 
were washed and the thymoquinone solutions were again re-added to regions one and 
two at the same concentrations and media was re-added to region three. The following 
day the plates were washed and 100µl of media added and cell viability was assessed 
using the MTS assay. 
 
This data was quantified via the MTS assay and then analyzed using the Calcusyn 
(Biosoft ®) software program, which utilizes the T.C. Chou method of determining 
synergy and antagonism.  The combination index was determined at a 25%, 50%, and 
75% toxicity level for each cell line and at each drug ratio (1:1, 1:4, and 4:1 
thymoquinone to cisplatin).  
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Sequential exposure to thymoquinone and cisplatin 
PA-1, A172, H460 cells were plated in 96 well plates at concentrations of 1 X 103 cells 
per well for PA-1 and A172 and 5 X 103 cells per well for H460 cells. The cells were 
allowed to adhere overnight before addition of thymoquinone and cisplatin. Each of the 
96 well plates were divided into regions: region one was thymoquinone and cisplatin, 
region two was thymoquinone alone, and region three was cisplatin alone. 
Thymoquinone or cisplatin were added to the 96 well plates at a ratio of 4:1, 
respectively. For PA-1 cells the concentrations used were 28-0.0068µM: 7-0.0017µM, 
for A172 the concentrations used were 448-7µM: 112-1.75µM, and for H460 the 
concentrations used were 1792-0.4375µM: 448 - 0.1094.  Each cell line was exposed to 
seven concentrations within the designated concentration range and these 
concentrations were diluted by one fourth starting from the top concentration. The 
protocol was as follows: on day one, cells were allowed to adhere, on day two, 
thymoquinone was added to regions one and two and media added to region three, or 
cisplatin was added to regions one and three and media was added to region two. On 
day three, the solution was removed from all regions and either thymoquinone was 
added to regions one and two with media added to region three or cisplatin was added 
to regions one and three and media was added to region two. On day four, the solution 
was removed from all regions and media was added at 100µl per well. The MTS assay 
was performed to assess cell viability. 
 
This data was quantified via the MTS assay and then analyzed using the Calcusyn 
(Biosoft ®) software program.  The combination index was determined at 25%, 50%, 
and 75% cell toxicity levels for each cell line at the drug ratio of 4:1 (thymoquinone to 
cisplatin). 
 
Concurrent exposure to thymoquinone and paclitaxel 
PA-1, A172, and H460 cells were plated in 96 well plates at concentrations of 3 X 103 
cells per well. Each 96 well plate was divided into three regions: region one contained 
thymoquinone and paclitaxel, region two contained thymoquinone alone, and region 
three contained paclitaxel alone. Thymoquinone and paclitaxel were added to the 96 
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well plates in ratios of 100:1, 400:1, and 1600:1 on separate plates respectively. For 
PA-1 cells at a 100:1 ratio (thymoquinone: paclitaxel) the concentrations were 32 - 
0.00781µM: 0.32 - 0.0000781µM, at a 400:1 ratio the concentrations were 128µM - 
0.03125: 0.32- 0.0000781µM, and at a 1600:1 ratio the concentrations were 512 - 
0.125µM: 0.32- 0.0000781µM. For A172 and H460 at a ratio of at 100:1 (thymoquinone: 
paclitaxel) the concentrations were 64 - 0.0156µM: 0.64 - 0.000156µM, at a 400:1 ratio 
the concentrations were 256 - 0.0625µM: 0.64 - 0.000156µM, and at a 1600:1 ratio the 
concentrations were 1024 –0.25µM: 0.64 - 0.000156µM. Each cell line was exposed to 
seven concentrations within the designated concentration range and hese 
concentrations were diluted by one-fourth stating from the top concentration. The 
protocol was as follows: on day 1 cells were allowed to adhere, on day two 
thymoquinone and paclitaxel were added to region one, thymoquinone was added to 
region two and paclitaxel was added to region three, the cells were allowed to incubate 
until day four, on day four the solution was removed from all regions and media was 
reapplied at 100µL per well. The MTS assay was performed to monitor cell viability after 
incubation for twenty-four hours. 
 
This data was quantified via the MTS assay and then analyzed using the Calcusyn 
(Biosoft ®) software program.  The combination index was determined at a 25%, 50%, 
and 75% toxicity level for each cell line and at the above drug ratios of 100:1, 400:1, 
and 1600:1 (thymoquinone to paclitaxel).  
 
Sequential exposure to thymoquinone and paclitaxel 
PA-1, A172, and H460 cells were plated in 96 well plates at concentrations of 1X 103 
cells per well. Each of the 96 well plates were divided into three regions: region one 
contained thymoquinone and paclitaxel, region two contained thymoquinone alone, and 
region three contained paclitaxel alone. Thymoquinone and paclitaxel were added to the 
96 well plates at a ratio of 1600:1. For PA-1 cells the concentrations used were 128-
0.031:0.08-0.0000195µM, for A172 and H460 cells the concentrations used were 512-
0.125:0.32-0.000078µM. These concentrations were diluted by one-fourth with seven 
concentrations applied within each range noted above. The protocol was as follows: on 
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day one cells were allowed to adhere, on day two thymoquinone was added to regions 
one and two and media added to region three, or paclitaxel was added to regions one 
and three and media was added to region two. These plates were incubated for forty-
eight hours. On day four the solutions were removed from all regions and either 
thymoquinone was added to regions one and two with media added to region three or 
paclitaxel was added to regions one and three and media was added to region two. 
These plates were again incubated for forty-eight hours. The MTS assay was performed 
to monitor cell viability. 
 
This data was quantified via the MTS assay and then analyzed using the Calcusyn 
(Biosoft ®) software program.  The combination index was determined at 25%, 50%, 
and 75% cell toxicity levels for each cell line at a drug ratio of 1600:1 (thymoquinone to 
paclitaxel). 
 
Analysis of additive, synergistic, or antagonistic effects  
The median-effect equation and combination index analysis was used to calculate the 
interaction between treatment modalities. This analysis determines if the effect is 
antagonistic, additive or synergistic. The analysis is termed median effect analysis and 
used extensively in biological systems. For further review see Chou TC (1976) and 
Chou TC et al., (1984). The mathematical equation of the median-effect equation is: 
fa/fu+ (D/Dm)m , where fa is the fraction affected by dose, fu is the fraction unaffected by 
the dose, D is the drug dosage, Dm is the dosage of the drug required to inhibit the 
growth of 50% of the cells and is determined from the x-intercept, and m is the 
coefficient signifying the sigmoidicity of the dose-effect curve. The logarithmic form of 
the median-effect equation was used to linearize the dose-response curves, and can be 
plotted to generate the median-effect plot. Log (D) plotted vs. log (fa/fu), the x-intercept 
obtained is log (Dm), from which the IC50 can be evaluated and the slope is the m value. 
The m and the Dm values obtained thereafter can be used to calculate the effective 
dose for any effect level (Bence, A. et al., 2003). 
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The combination index (CI) is used to determine synergism or antagonism. The 
equation is based on the multiple-drug effect equation. A CI value of one indicates that 
the effect of one drug is additive to the second, a CI value of greater than one indicates 
antagonism between the two drugs, and a CI value of less than one indicates synergism 
between the drugs,. The equation used to calculate CI is as follows: (D)1/(Dx)1 + 
(D)2/(Dx)2 + α (D)1(D)2/(Dx)1(Dx)2, where (Dx)1 and (Dx)2 are the doses for x% inhibition 
by drug 1 and drug 2 alone (Chou et al. 1984). These values are obtained from the 
median-effect equation. (D)1 and (D)2 are the doses in combination that inhibit cell 
growth by x%.  A more detailed description of degrees of synergism and antagonism is 
listed in the table 6.1 adapted from Chou and Hayball (1996). 
 
 
Table 6.1: Combination Index Values (CI) 
 
Range of Combination Index Values Description of Effect 
< 0.1 Very strong synergism 
0.10 – 0.30 Strong synergism 
0.30 – 0.70  Synergism 
0.70 – 0.85 Moderate synergism 
0.85 – 0.90 Slight synergism 
0.90 – 1.10 Nearly additive 
1.10 – 1.45 Moderate antagonism 
1.45 – 3.30 Antagonism 
3.30 – 10  Strong antagonism 
> 10 Very strong antagonism 
 
The entire analysis was performed with the automated computer software Calcusyn 
(Biosoft®, Ferguson, MO USA).  
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Cell Cycle Analysis using Flow Cytometry 
A172 and PA-1 cells were plated in 10ml of media in 100cm dishes at concentrations of 
2 X 106 and 1 X 106 cells/dish, respectively.  The cells were allowed to adhere overnight 
before addition of thymoquinone (21µM, and 8µM, respectively). These concentrations 
were determined to result in 50% cellular death. At 48 hours post drug treatment the 
cells were harvested, pelleted, washed with cold PBS, and resuspended in 0.5ml of 
PBS.  5ml of 70% ethanol was added drop wise while vortexing. The cells were left in 
fixative at 4°C for at least 15 minutes. The cells were then centrifuged and resuspended 
in a propidium iodide/RNAse A solution at a final concentration of 1 X 106 cells/ml. The 
cells were incubated for thirty minutes at 37°C before analysis by flow cytometry. 
Propidium Iodide staining allowed for the percentage of cells in G(1), S, and G(2)/M 
phase of the cell cycle to be determined. 
 
Determination of Apoptosis or Necrosis using Flow Cytometry 
A172 and PA-1 cells were plated in 10ml of media in 100cm dishes at concentration of 2 
X 106 and 1 X 106 cells/dish, respectively.  The cells were allowed to adhere overnight 
before addition of thymoquinone (21µM, and 8µM, respectively).  At 48 hours post drug 
treatment the cells were harvested, pelleted (with initial media solution added), re-
pelleted, and resuspended in media. A cell count was then taken and approximately 1 X 
106 cells were added to polystyrene tubes and pelleted. The media was removed and 
replaced with 1ml of binding buffer. Cells were pelleted, and then suspended in 200µl of 
binding buffer, except tube 5, which was resuspended in 200µl of 70% ethanol. Five 
control tubes of cells, which were not exposed to thymoquinone, were required. The 
experiment was carried out according to the table below: 
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Table 6.2 Experimental Setup for Flow Cytometry 
 
Tube # PA-1 untreated cells A172 untreated cells 
1 Nothing Added Nothing Added 
2 Added 5µl Annexin Added 5µl Annexin 
3 Added 10µl PI Added 10µl PI 
4 Added 5µl annexin and 
10µl PI 
Added 5µl annexin and 
10µl PI 
5 Added 5µl annexin and 
10µl PI in 200µl ethanol 
Added 5µl annexin and 
10µl PI in 200µl ethanol 
6 Added 5µl annexin and 
10µl PI 
Added 5µl annexin and 
10µl PI 
 
All of the tubes were then incubated for five to fifteen minutes in the dark, at room 
temperature before addition of 800µl binding buffer. The tubes were analyzed by flow 
cytometry and the percentage of apoptotic and necrotic cells was determined. 
 
Cytostatic or Cytotoxic Determination 
PA-1 and A172 cells were plated in 96 well plates (two plates per cell line: one plate as 
a control and the other plate to be treated with thymoquinone) at a concentration of 3 
X103 cells per well. After 24 hours thymoquinone was administered to one 96 well plate 
from each cell line in concentrations ranging from 128-0.03125µM. The plates were 
incubated for 48 hours at 37°C. To the other 96 well plate from each cell line the MTS 
assay was performed. The time at which the MTS assay was started was noted (and 
called the time zero reading) and readings were collected every half hour for up to four 
hours. These plates were discarded. To the plates with thymoquinone, after the 48 hour 
incubation period the plates were washed and 100µl of media was added. The MTS 
assay was started at the exact time of the day as the plates without thymoquinone and 
readings were collected every thirty minutes until a value of 1.00 had been reached in 
the control wells. Using the absorbance measurements collected at time zero (Tz) (all 
control wells), and from the thymoquinone treated cells (Ti) after matching MTS 
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development time, the cytotoxicity can be assessed.  More specifically an LD50 can be 
calculated with the following equation [(Ti-Tz)/Tz] x 100 = -50.  More details about 
antineoplastic drug screening can be found at (National Cancer Institute) web site under  
the In Vitro Cell Line Screening Project (IVCLSP).  
 
Statistical Analysis 
All statistical analysis were conducted using the Microsoft Excel program. Statistical 
differences were analyzed using two-sample student t-test.  Significance was 
determined at p ≤ 0.05. 
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Chapter Seven 
Results 
 
Cell Proliferation and Viability Assays 
24-hour exposure experiments 
Initial cell viability assays were undertaken to see if thymoquinone exhibited its cytotoxic 
effects in a p53-dependent manner. The human ovarian cancer cells, PA-1 with wild 
type p53, CAOV-3 with mutated p53, and SKOV-3 with null p53, were used to elucidate 
the effects of thymoquinone. For PA-1 cells treated with thymoquinone, the IC50 was 
determined to be 7.26µM ± 0.21. For CAOV-3 cells, the IC50 was 45.22µM ± 5.88. The 
IC50 for SKOV-3 cells  was found to be 20.16µM ± 0.41.   All experiments were done in 
quadruplicate per plate and each experiment was repeated at least three times.  All 
values are reported as the standard error of the mean. The data shows that the PA-1 
cells are most susceptible to thymoquinone, which suggests that p53 maybe important 
for activity.  The data is shown in figure 7.1. 
 
Figure 7.1: Effect of thymoquinone on PA-1, CAOV-3, and SKOV-3 cell lines after 
24 hours of exposure.  
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48-hour exposure experiments 
The cell lines PA-1, A172, A549 and H460 cells all posses wild type p53.  PA-1 cells 
treated with thymoquinone had an IC50 of 4.35µM ± 0.63. A172 cells exposed to 
thymoquinone had an IC50 was of 18.41µM ± 1.70, and H460 cells exposed to 
thymoquinone had an IC50 of 40.1µM ± 2.04. For A549 cells treated with thymoquinone 
over the range of 256 to 0.0625µM, the IC50 was found to be 17.31µM ± 4.70. All 
experiments were done in quadruplicate per plate and each experiment was repeated at 
least three times.  All values are reported as the standard error of the mean. The data is 
demonstrated in figure 7.2. and suggests that wild type p53 does not clearly indicate 
sensitivity to thymoquinone. 
 
Figure 7.2: Effect of thymoquinone on PA-1, A172, H460, and A549 cell lines after 
48 hours.  
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48-hour exposure followed by 24 hours of recovery in media 
The cell line PA-1, A172, and H460 were subjected to thymoquinone for 48 hours 
followed by recovery in media for 24 hours. The IC50 for PA-1 cells was determined to 
be 1.14µM ± 0.19. A172 cells exposed to thymoquinone have an IC50 of 4.09µM ± 1.27.  
In H460 cells the IC50 was found to be 27.88µM ± 2.61. All experiments were done in 
quadruplicate per plate and each experiment was repeated at least three times. All 
values are reported as the standard error of the mean. The data is demonstrated in 
figure 7.3.  These data suggest that growth inhibition/cytotoxicity is not rapidly reversible 
after drug removal. 
 
Figure 7.3: Effect of thymoquinone on PA-1, A172, and H460 cell lines after 48 
hours followed by 24 hour recovery in media.  
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120-hour exposure experiments: 
PA-1, A172, H460, and A549 cells were exposed to thymoquinone for 120 hours.  The 
IC50s for PA-1, A172, and A549 were determined to be: 0.39µM ± 0.13, 3.83µM ± 0.17, 
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and 4.67µM ± 0.61, respectively. H460 cells exposed to thymoquinone had an IC50 of 
16.53µM ± 1.00. All treatments were done in quadruplicate per plate and each 
experiment was repeated at least three times. All values are reported as the standard 
error of the mean. This data is demonstrated in figure 7.4.and suggest that prolonged 
exposure may optimize growth inhibition/cytoxic activity. 
 
Figure 7.4: Effect of thymoquinone on PA-1, A172, H460, and A549 cell lines after 
120 hours.  
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p53 quantification by Western Blotting 
In order to study the ability of thymoquinone to mediate growth-signaling pathways in 
neoplastic cells, Western blots were performed to quantify changes in p53 levels 
between untreated cells and those treated with thymoquinone. p53 protein was the 
protein of choice to monitor because it is a known tumor suppressor protein and is 
mutated in 50% of human cancers. Many chemotherapeutic agents exert their effects 
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through upregulating p53. A549 cells treated with 25nM paclitaxel served as a positive 
control.  
 
The cells used in this study were PA-1, A172, H460, and A549. p53 is reported as the 
percent of positive control prior to comparisons between untreated and thymoquinone 
treated cells.  The results are as follows: 
 
PA-1 cells 
In PA-1 cells the average p53 level in untreated cells was 23.32% while the average 
p53 level in thymoquinone treated cells was 52.94%, relative to the A549 treated 
positive control. This is a 127% increase in the p53 levels in the thymoquinone treated 
cells versus the untreated cells. Using a two sample t-test these values were found to 
be significantly different (p= 5.17 X 10-7). A total of six thymoquinone treated protein 
samples were prepared and utilized, and each sample was subjected to Western blot 
analysis and repeated at least three times. All values are reported as the standard error 
of the mean. Figure 7.6 represents a sample Western blot analysis. 
 
Figure 7.5: Western blot analysis demonstrating up regulation of p53 by 
thymoquinone in PA-1 cells. The lanes are as follows (1) untreated A549 cells, (2) 
A549 cells treated with 25nM paclitaxel, serving as the positive control, (3) 
untreated PA-1 cells, (4-7) treated PA-1 cells.  
                               
       
        
 
 
A172 cells 
In A172 cells the average p53 level in untreated cells was 26.21% while the average 
p53 level for thymoquinone treated cells was 38.55%, relative to the A549 treated 
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positive control. This is a 47% increase in p53 levels in the thymoquinone treated cells 
versus the untreated cells. Using a two sample t-test these values were found to be 
significantly different (p= 0.04). A total of four thymoquinone treated protein samples 
were prepared and utilized, and each sample was subjected to Western blot analysis 
and repeated at least three times. All values are reported as the standard error of the 
mean.  The data is illustrated if figure 7.6. 
 
H460 cells 
In H460 cells the average p53 level in untreated cells was 37.75% while the average 
p53 level in thymoquinone treated cells was 67.03%, relative to the A549 positive 
control. This is a 76% increase in the p53 levels in the treated cells versus the untreated 
cells. Using a two sample t-test these values were found to be significantly different (p= 
0.008). A total of four thymoquinone treated protein samples were prepared and utilized, 
and each sample was subjected to Western blot analysis and repeated at least three 
times. All values are reported as the standard error of the mean. This data is illustrated 
in figure 7.6. 
 
A549 cells 
In A549 cells the average p53 level in untreated cells was 18.07% while the p53 level 
for thymoquinone treated cells was 29.49%, relative to the A549 positive control. This is 
a 61% increase in the p53 levels for the treated cells versus the untreated cells. Using a 
two sample t-test these values were found to be significantly different (p= 0.003). A total 
of four thymoquinone treated protein samples were prepared and utilized, and each 
sample was subjected to Western blot analysis and repeated at least three times. All 
values are reported as the standard error of the mean. This data is illustrated in figure 
7.6. 
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Figure 7.6: The comparative levels of p53 protein in various cell lines, which have 
been treated with or without thymoquinone. The values are represented as a 
percent of the control. p≤ 0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* indicates statistical significance (p < 0.05) 
 
Combination Drug Therapy Studies 
Concurrent exposure to thymoquinone and cisplatin 
PA-1, A172, and H460 cells were all exposed concurrently to thymoquinone and 
cisplatin.  
 
PA-1 cells 
Administration of thymoquinone and cisplatin in a 1:1 ratio resulted in moderate 
antagonism at the 25% toxicity level and antagonism at the 50% and 75% toxicity 
levels. At a 1:4 ratio the treatment resulted in a nearly additive effect at 25% toxicity, a 
moderate antagonistic effect at 50% and 75% toxicity. .At the 4:1 ratio the combination 
treatment resulted in antagonism at 25% toxicity, moderate antagonism at 50% toxicity, 
and was nearly additive at 75% toxicity. All values were determined with an n≥ 3 and all 
values are reported as the standard error of the mean.  This data is summarized in table 
7.1. 
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Table 7.1: Effect of concurrent exposure of thymoquinone and cisplatin on PA-1 
cells. The data represents an n≥3. 
 
PA-1 cells with concurrent exposure to thymoquinone and cisplatin 
1:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.37 1.81 1.92 
SEM 0.16 0.13 0.16 
1:4 ratio 
% Toxicity* 25 50 75 
Combination Index 1.02 1.14 1.29 
SEM 0.07 0.05 0.06 
4:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.95 1.27 1.01 
SEM 0.27 0.08 0.07 
* The percent of non-viable cells. 
 
A172 cells 
Administration of thymoquinone and cisplatin in a 1:1 ratio resulted in antagonism at the 
25, 50, and 75% toxicity levels. At a 1:4 ratio the combination effect was also 
antagonistic at the 25, 50 and 75% toxicity levels. At a 4:1 ratio the combination drug 
effect was moderately antagonistic at 25%, 50%, and 75% toxicity. All values were 
determined with an n≥ 3 and all values are reported as the standard error of the mean. 
This data is summarized in table 7.2. 
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Table 7.2: Effect of concurrent exposure of thymoquinone and cisplatin on A172 
cells. The data represents an n≥3. 
 
A172 cells with concurrent exposure to thymoquinone and cisplatin 
1:1 ratio 
% Toxicity* 25 50 75 
Combination Index 2.54 1.87 1.69 
SEM 0.05 0.09 0.12 
1:4 ratio 
% Toxicity* 25 50 75 
Combination Index 2.32 2.48 2.69 
SEM 0.17 0.01 0.48 
4:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.34 1.16 1.10 
SEM 0.03 0.03 0.05 
* The percent of non-viable cells. 
 
H460 cells 
Administration of thymoquinone and cisplatin in a 1:1 ratio resulted in moderate 
antagonism at 25% toxicity levels, and antagonism at the 50 and 75% toxicity levels. At 
a 1:4 ratio the effect of the drug combination was moderate antagonism at 25% and 
50% toxicity levels and full antagonism at a 75% toxicity level. At the 4:1 ratio the 
combinatorial effect of the drug treatment resulted in antagonism at the 25% toxicity 
level, nearly additive at the 50% toxicity level, and moderate synergism at 75% toxicity. 
All values were determined with an n≥ 3 and all values are reported as the standard 
error of the mean. This data is summarized in table7.3. 
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Table 7.3: Effect of concurrent exposure of thymoquinone and cisplatin on H460 
cells. The data represents an n≥3. 
 
H460 cells with concurrent exposure to thymoquinone and cisplatin 
1:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.41 1.54 1.93 
SEM 0.30 0.14 0.31 
1:4 ratio 
% Toxicity* 25 50 75 
Combination Index 1.29 1.38 1.67 
SEM 0.27 0.20 0.05 
4:1 ratio 
% Toxicity* 25 50 75 
Combination Index 2.01 1.05 0.838 
SEM 0.29 0.09 0.21 
* The percent of non-viable cells. 
 
Sequential Exposure to thymoquinone and cisplatin 
PA-1, A172, and H460 cells were all exposed sequentially to thymoquinone and 
cisplatin.  
 
PA-1 cells 
Administration of thymoquinone followed by cisplatin resulted in an overall nearly 
additive effect at 25%, 50%, and 75% toxicity levels. Administration of cisplatin followed 
by thymoquinone resulted in moderate antagonism at 25% toxicity, a nearly additive 
effect at 50% toxicity, and moderate synergism at 75% toxicity. All values were 
determined with an n≥ 3 and all values are reported as the standard error of the mean. 
This data is summarized in table 7.4 below . 
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Table 7.4: Effect of thymoquinone and cisplatin added sequentially at a ratio of 
4:1 on PA-1 cells. The data represents an n≥3. 
 
PA-1 cells treated with thymoquinone and cisplatin sequentially at a 4:1 ratio (thymoquinone to 
cisplatin) 
Thymoquinone first 
% Toxicity* 25 50 75 
Combination Index 0.95 0.92 0.94 
SEM 0.05 0.06 0.08 
Cisplatin first 
% Toxicity* 25 50 75 
Combination Index 1.30 0.99 0.84 
SEM 0.16 0.07 0.07 
* The percent of non-viable cells. 
 
A172 cells 
Administration of thymoquinone followed by cisplatin resulted in an overall moderate 
synergistic effect 25%, 50%, and 75% toxicity levels. Administration of cisplatin followed 
by thymoquinone resulted in moderate antagonism at 25%, 50%, and 75% toxicity 
levels. All values were determined with an n≥ 3 and all values are reported as the 
standard error of the mean. This data is summarized in table 7.5. 
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Table 7.5: Effect of thymoquinone and cisplatin added sequentially at a ratio of 
4:1 on A172 cells. The data represents an n≥3. 
 
A172 cells treated with thymoquinone and cisplatin sequentially at a 4:1 ratio (thymoquinone to 
cisplatin) 
Thymoquinone first 
% Toxicity* 25 50 75 
Combination Index 0.83 0.75 0.70 
SEM 0.06 0.04 0.06 
Cisplatin first 
% Toxicity* 25 50 75 
Combination Index 1.32 1.18 1.13 
SEM 0.01 0.05 0.09 
* The percent of non-viable cells. 
 
H460 cells 
Administration of thymoquinone followed by cisplatin resulted in moderate synergism at 
25%, slight synergism at 50%, and a nearly additive effect 75% toxicity levels. 
Administration of cisplatin followed by thymoquinone resulted in moderate antagonism 
at 25% toxicity, and a nearly additive effect 50%, and 75% toxicity levels.  All values 
were determined with an n≥ 3 and all values are reported as the standard error of the 
mean. This data is summarized in table 7.6. 
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Table 7.6: Effect of thymoquinone and cisplatin added sequentially at a ratio of 
4:1 on H460 cells. The data represents an n≥3. 
 
H460 cells treated with thymoquinone and cisplatin sequentially at a 4:1 ratio (thymoquinone to 
cisplatin) 
Thymoquinone first 
% Toxicity* 25 50 75 
Combination Index  0.84 0.88  0.93  
SEM  0.01 0.04  0.06  
Cisplatin first 
% Toxicity* 25  50 75 
Combination Index  1.19 0.97  0.95  
SEM  0.08 0.06  0.11  
* The percent of non-viable cells. 
 
Concurrent exposure to thymoquinone and paclitaxel 
PA-1, A172, and H460 cells were all exposed concurrently to thymoquinone and 
paclitaxel.  
 
PA-1 cells  
Administration of thymoquinone and paclitaxel in a 100:1 ratio resulted in moderate 
antagonism at the 25% and 50% toxicity, and antagonism at 75% toxicity. At a 400:1 
ratio the drug combination was moderately antagonistic at 25%, 50%, and 75% toxicity 
levels. At a 1600:1 ratio the drug combination was synergistic at the 25%, 50%, and 
75% toxicity levels. All values were determined with an n≥ 3 and all values are reported 
as the standard error of the mean.  This data is summarized in table 7.7. 
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Table 7.7: Effect of the concurrent exposure of thymoquinone and paclitaxel on 
PA-1 cells. The data represents an n≥3. 
 
PA-1 cells with concurrent exposure to thymoquinone and paclitaxel 
100:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.20 1.34 1.48 
SEM 0.10 0.04 0.05 
400:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.34 1.28 1.22 
SEM 0.12 0.05 0.05 
1600:1 ratio 
% Toxicity* 25 50 75 
Combination Index 0.58 0.57 0.617 
SEM 0.12 0.14 0.16 
* The percent of non-viable cells. 
 
A172 cells 
Administration of thymoquinone and paclitaxel in a 100:1 ratio resulted in moderate 
antagonism at 25 and 50% toxicity levels and antagonism at the 75% level. At a 400:1 
ratio the drug effect was antagonistic at 25% toxicity, moderately antagonistic at 50% 
toxicity, and nearly additive at 75% toxicity. At a 1600:1 ratio the combinatorial drug 
effect was nearly additive at 25%, 50%, and 75% toxicity levels. All values were 
determined with an n≥ 3 and all values are reported as the standard error of the mean.  
This data is summarized in table 7.8. 
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Table 7.8: Effect of the concurrent exposure of thymoquinone and paclitaxel on 
A172 cells. The data represents an n≥3. 
 
A172 cells with concurrent exposure to thymoquinone and paclitaxel 
100:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.11 1.29 1.56 
SEM 0.25 0.08 0.14 
400:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.77 1.28 1.04 
SEM 0.20 0.11 0.18 
1600:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.01 1.04 1.02 
SEM 0.05 0.12 0.18 
* The percent of non-viable cells. 
 
H460 cells 
Administration of thymoquinone and paclitaxel in a 100:1 ratio resulted in moderate 
synergism at 25% toxicity, slight synergism at 50% toxicity, and moderate antagonism 
at 75% toxicity. At a 400:1 ratio moderate antagonism was the result at the 25% toxicity 
level, moderate synergism at the 50% toxicity level, and synergism at the 75% toxicity 
level. At a 1600:1 ratio the combination drug effect was moderate antagonism at 25% 
toxicity, moderately synergistic at 50% toxicity, and synergistic at 75% toxicity. All 
values were determined with an n≥ 3 and all values are reported as the standard error 
of the mean.  This data is summarized in table 7.9. 
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Table 7.9: Effect of the concurrent exposure of thymoquinone and paclitaxel on 
H460 cells. The data represents an n≥3. 
 
H460 cells with concurrent exposure to thymoquinone and paclitaxel 
100:1 ratio 
% Toxicity* 25 50 75 
Combination Index 0.74 0.88 1.43 
SEM 0.10 0.10 0.45 
400:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.32 0.71 0.54 
SEM 0.29 0.09 0.03 
1600:1 ratio 
% Toxicity* 25 50 75 
Combination Index 1.28 0.728 0.48 
SEM 0.09 0.05 0.07 
* The percent of non-viable cells. 
 
Sequential exposure to Thymoquinone and Paclitaxel 
PA-1, A172, and H460 cells were all exposed sequentially to thymoquinone and 
paclitaxel.  
 
PA-1 cells 
Administration of thymoquinone followed by paclitaxel resulted in an overall slight 
synergism at 25%, 50%, and 75% toxicity levels. Administration of paclitaxel followed by 
thymoquinone resulted in antagonism at 25%, 50%, and 75% toxicity levels.  All values 
were determined with an n≥ 3 and all values are reported as the standard error of the 
mean. This data is summarized in table 7.10. 
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Table 7.10: Effect of thymoquinone and paclitaxel added sequentially at a ratio of 
1600:1 on PA-1 cells. The data represents an n≥3. 
 
PA-1 cells treated with thymoquinone and paclitaxel sequentially at a 1600:1 ratio (thymoquinone 
to paclitaxel) 
Thymoquinone first 
% Toxicity* 25 50 75 
Combination Index 0.89 0.85 0.86 
SEM 0.02 0.08 0.17 
Paclitaxel first 
% Toxicity* 25  50 75 
Combination Index 1.87 1.67 1.53 
SEM 0.24 0.22 0.20 
* The percent of non-viable cells. 
 
A172 cells 
Administration of thymoquinone followed by paclitaxel resulted in a synergism effect at 
25%, 50%, and 75% toxicity levels. Administration of paclitaxel followed by 
thymoquinone resulted in a nearly additive effect at 25% toxicity, a moderately 
synergistic effect at 50% and 75% toxicity levels.  All values were determined with an n≥ 
3 and all values are reported as the standard error of the mean. This data is 
summarized in table 7.11. 
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Table 7.11: Effect of thymoquinone and paclitaxel added sequentially at a ratio of 
1600:1 on A172 cells. The data represents an n≥3. 
 
A172 cells treated with thymoquinone and paclitaxel sequentially at a 1600:1 ratio (thymoquinone 
to paclitaxel) 
Thymoquinone first 
% Toxicity* 25 50 75 
Combination Index 0.66 0.64 0.66 
SEM 0.07 0.07 0.08 
Paclitaxel first 
% Toxicity* 25  50 75 
Combination Index 1.04 0.80 0.77 
SEM 0.22 0.18 0.13 
* The percent of non-viable cells. 
 
H460 cells 
Administration of thymoquinone followed by paclitaxel resulted in an antagonistic effect 
at 25%, 50%, and 75% toxicity levels. Administration of paclitaxel followed by 
thymoquinone resulted in an overall slight synergistic effect at 25%, 50%, and 75% 
toxicity levels.  All values were determined with an n≥ 3 and all values are reported as 
the standard error of the mean. This data is summarized in table 7.12. 
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Table 7.12: Effect of thymoquinone and paclitaxel added sequentially at a ratio of 
1600:1 on H460 cells. The data represents an n≥3. 
 
H460 cells treated with thymoquinone and paclitaxel sequentially at a 1600:1 ratio (thymoquinone 
to paclitaxel) 
Thymoquinone first 
% Toxicity* 25 50 75 
Combination Index 1.68 1.60 1.63 
SEM 0.36 0.20 0.07 
Paclitaxel first 
% Toxicity* 25  50 75 
Combination Index 0.87 0.89 0.87 
SEM 0.13 0.08 0.15 
* The percent of non-viable cells. 
 
Effect of Thymoquinone on Cell Cycle Distribution  
PA-1 and A172 cells were treated with thymoquinone at a dose which caused 50% cell 
death (7uM and 21µM, respectively).   These cells, as well as, untreated PA-1 and A172 
cells were analyzed by flow cytometry to monitor cell cycle distribution. Thymoquinone 
treatment of PA-1 cells and A172 cells with the above mentioned dose did not cause a 
significant accumulation of cells in the G(0)-G(1), S, or G(2)-M phases of the cell cycle 
after 48 hours of thymoquinone treatment. The results are summarized in figure 7.7 and 
figure 7.8.  
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Figure 7.7: The cell cycle distribution of PA-1 cells, either with or without 
thymoquinone. All values are represented as the percent of cells in different 
phases of the cell cycle.  
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Figure 7.8: The cell cycle distribution of A172 cells, either with or without 
thymoquinone. All values are represented as the percent of cells in different 
phases of the cell cycle.  
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Thymoquinone mediated apoptosis and necrosis 
PA-1 and A172 cells were treated with thymoquinone at a dose which caused 50% cell 
death at 7µM and 21µM respectively. These cells as well as untreated PA-1 and A172 
cells were treated with annexin and/or propidium iodide to distinguish between apoptotic 
and necrotic cellular death. These cells were analyzed by flow cytometry. The ratio of 
apoptotic to necrotic cells was determined to monitor if an increase in apoptosis 
occurred following thymoquinone treatment.  Thymoquinone treatment of PA-1 cells and 
A172 cells at the above mentioned doses did not cause a significant change in the 
number of apoptotic to necrotic cells. All values were determined with an n≥ 3 and all 
values are reported as the standard error of the mean. The data is summarized in 
figures 7.9 and 7.10 
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Figure 7.9: Ratio of apoptotic/necrotic PA-1 cells with or without thymoquinone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10: Ratio of apoptotic/necrotic A172 cells with or without thymoquinone.  
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PA-1 cells and A172 cells were treated with thymoquinone over a concentration range 
of 128-0.3125 µM for 48 hours to monitor if thymoquinone functioned as a cytotoxic or 
cytostatic agent.  The experiments were performed and analyzed using methods set 
forth by the In Vitro Cell Line Screening Project (IVCLSP). The control cells (cells 
exposed to media for 48 hours) are displayed when x=0.  Values of y larger than the 
control indicate increased cellular growth following drug treatment. Values of y less than 
the control but greater than zero indicated cellular growth inhibition (cytostatic effect). 
When the y-axis equals zero, total growth inhibition (TGI) has occurred, this is when the 
number of cells prior to thymoquinone treatment equals the number of cells after 48 
hours of drug treatment indicating that thymoquinone has completely inhibited cells from 
growing. Values of y less than zero indicate cellular death (cytotoxic effect). Based on 
this methodology it was determined that thymoquinone acts as a cytotoxic agents 
because the relative number of cells at the end of thymoquinone treatment was less 
than the number of cells at time zero (start of thymoquinone treatment) (National 
Cancer Institute).  The graph for A172 cells (n = 3) is shown in figure 7.11. 
 
Figure 7.11: The type of inhibition produced by thymoquinone in A172 cells 
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Chapter Eight 
 
Discussion 
Queries 
The research conducted herein focused on thymoquinone, the active constituent of the 
plant Nigella sativa. The following queries were raised. Is thymoquinone cytotoxic 
through a mechanism which up regulates p53? This query was raised because it had 
previously been reported that thymoquinone causes G(1) arrest (Shoeib et al. 2002). 
G(1) arrest is known to be initiated by up regulation of the tumor suppressor gene p53. 
If thymoquinone initiated its function through this pathway then its cytotoxic properties 
should be greatly reduced in cells which have mutated or null p53 status. The next 
question was: could the up regulation of the p53 protein be demonstrated following 
thymoquinone treatment? At this point in time p53 up regulation had been speculated 
but not proven.  
 
Another query was: can thymoquinone alter the cytotoxicity of other known 
chemotherapeutic agents and is its effect, antagonistic, additive, or synergistic, does 
this effect change if the drugs are given sequentially instead of concurrently, and does 
this effect vary if thymoquinone is administered with a cell cycle specific agent 
(paclitaxel) or with a non-cell cycle specific agent (cisplatin)?  This study was important 
to undertake because in some parts of the world Nigella sativa is consumed in high 
levels by the general population. If thymoquinone is found to antagonize the effects of 
chemotherapy it would be of importance for physicians in these regions of the world to 
be able to make their patients aware of this possible drug-drug interaction. However, if 
synergistic this may be a new treatment option for physicians 
 
Does thymoquinone treatment result in necrosis or apoptosis? This endpoint was 
evaluated to further elucidate thymoquinone mechanism of action as a 
chemotherapeutic agent. In addition it would be useful to know if thymoquinone is a true 
cytotoxic or cytostatic agent. This would allow clinicians in the near future to decide on 
the dosing regimen of thymoquinone, if it proves to be of clinical importance. 
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Summary of Research  
The initial study evaluating thymoquinone’s effects on p53 status indicated that the PA-1 
cells (wild type p53) were the most sensitive. Based on this, studies were conducted in 
cell types which only express wild-type p53. From these studies it was found that 
thymoquinone was cytotoxic to all cell lines in the micro-molar range. These studies 
were repeated at various time points (48 to 120 hours) and it appeared that the degree 
of cytotoxicity was directly related to the length of exposure. These cells were then 
analyzed by Western blot analysis. All p53 wild type cell lines tested had a significant 
increase (p≤ 0.05) in p53 levels after treatment with thymoquinone as compared to their 
untreated counterparts.   
 
The drug combination studies with concurrent exposure to thymoquinone and cisplatin 
in the cell types tested (PA-1, A172, and H460) revealed some degree of antagonism. 
These results suggest that it may not be beneficial to combine these drugs concurrently. 
The ratio that caused the least antagonism was the 4:1 ratio. Hence this ratio was used 
to assess the efficacy of the sequential combination therapy. 
 
When thymoquinone was administered first followed by cisplatin, a nearly additive effect 
was observed in PA-1 cells. The same effect was seen when cisplatin was administered 
first. Sequential administration of these two drugs seemed to have a more promising 
effect than when given concurrently in PA-1 cells. When thymoquinone was 
administered first followed by cisplatin a moderate synergistic effect was observed in 
A172 cells. Interestingly, a moderate antagonistic effect was seen when cisplatin was 
administered first in A172 cells.  Sequential administration of thymoquinone first, 
followed by cisplatin may have the most beneficial effect of the possible combination 
therapies tested. When thymoquinone was administered first followed by cisplatin an 
overall slight synergistic effect was observed in H460 cells. A nearly additive effect 
occurred when cisplatin was administered followed by thymoquinone. Sequential 
administration of thymoquinone first, followed by cisplatin may have the most beneficial 
effect of the possible combination therapies tested in the H460 cell line. These sets of 
 64
experiments suggest that sequential administration of thymoquinone with cisplatin 
seemed more efficacious than concurrent administration. However, the degree of 
efficacy and order of administration is cell line dependent. 
 
Thymoquinone was also monitored when given concurrently and sequentially with 
paclitaxel. The following cell lines were used; PA-1, A172 and H460. For PA-1 and 
A172 cells overall antagonism was seen at the lower drug ratios while the high drug 
ratio there was an additive effect for the A172 cells and synergy in the PA-1 cells. For 
H460 cells some degree of synergism was seen in all drug ratios. The ratio that resulted 
in maximum synergy was the 1600:1 ratio. Hence this ratio was used to assess the 
efficacy of the sequential combination therapy. 
 
When thymoquinone was administered first followed by paclitaxel a slight synergistic 
effect was observed in PA-1 cells. Interestingly, antagonism was seen when paclitaxel 
was administered first. Sequential administration of thymoquinone followed by paclitaxel 
seemed to have a most promising effect of the possible combination therapies. When 
thymoquinone was administered first followed by paclitaxel a synergistic effect was 
observed in A172 cells. A nearly additive to moderate synergistic effect was observed 
when paclitaxel was administered first. Sequential administration of thymoquinone first 
followed by paclitaxel may have a most beneficial effect of the possible combination 
therapies tested for A172 cells. When thymoquinone was administered first followed by 
paclitaxel an overall antagonistic effect was observed in H460 cells. Surprisingly, a 
slight synergistic effect occurred when paclitaxel was administered followed by 
thymoquinone. Sequential administration of paclitaxel first followed by thymoquinone 
may have the most beneficial effect of the possible combination therapies tested for 
H460 cells. These sets of experiments suggest that sequential administration of 
thymoquinone with paclitaxel seemed more efficacious than concurrent administration.  
 
PA-1 and A172 cells appeared to be the most sensitive to thymoquinone treatment, for 
this reason the remainder of the studies focus only on these two cell lines. For both cell 
lines, no significant difference was observed in cell cycle distribution between the 
 65
untreated control cells and the thymoquinone treated cells. These cells were also 
monitored to determine the effect of thymoquinone on apoptotic versus necrotic death. 
No significant difference was observed in the apoptotic:necrotic ratio between the 
untreated control cells and the thymoquinone treated cells in these cell lines. Lastly, PA-
1 and A172 cells were used to determine if thymoquinone exerts its effects either by 
being a cytotoxic or a cytostatic agent. It was found that thymoquinone functioned as a 
cytotoxic agent in both these cell lines.  
 
Interpretations of data 
Thymoquinone was most effective in the ovarian cancer cell type with wild-type p53. 
This result supports previous findings by Shoeib et al. 2002, who demonstrated that 
thymoquinone causes in vitro inhibition of growth and induction of apoptosis in cancer 
cells, with cell cycle arrest occurring at  G(1). G(1) arrest is known to be initiated by up 
regulation of the tumor suppressor gene p53. If thymoquinone initiated its function 
through this pathway then its cytotoxic properties should be greatly enhanced in cells 
which have wild-type p53 status.  
 
Thymoquinone was cytotoxic to all cell lines tested in the micro molar range. This result 
supports the previous findings by Worthen et al. 1998 which examined thymoquinone’s 
cytotoxic properties in various human cancers compared to their MDR-variants.  This 
study found that thymoquinone was cytotoxic in both the cell lines tested and their 
MDR-variants in the micro-molar range.  
 
The increase in p53 levels of the thymoquinone treated cancer cells supports the 
hypothesis by Shoeib et al. 2002., that thymoquinone exerts its effect through a p53 
mediated pathway. 
 
Combination drug therapy studies were undertaken to determine how thymoquinone 
behaves with other cytotoxic agents. Since thymoquinone is believed to work by halting 
cellular progression at G(1), it was hypothesized that its administration with a cell cycle 
non-specific agent like cisplatin would result in an additive to synergistic effect because 
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the two drug would work through different pathways. The concurrent thymoquinone and 
cisplatin studies however indicated that this combination was antagonistic in all tested 
cell lines. The exact mechanism by which this effect occurs is not known but it is 
possible that cisplatin and thymoquinone react with each other to decrease the cytotoxic 
capacity of each drug alone.  When the two agents were given sequentially with 
thymoquinone first the PA-1 cells exhibited a nearly additive effect and the A172 and 
H460 cells showed some degree of synergism.  When the cells were exposed to 
cisplatin first, PA-1 and H460 cell lines exhibited a nearly additive effect whereas the 
effect on A172 cells was antagonistic. These results are in agreement with previous 
studies done in vivo by Badary et al. 1997, which showed that thymoquinone enhanced 
the activity of cisplatin in mice when given both prior and following cisplatin treatment. 
The discrepancy in the A172 cell line is not clear, further studies need to be carried out 
in this particular cell line. 
 
It was hypothesized that administration of thymoquinone with paclitaxel would show 
antagonism because paclitaxel exerts its effect at M-phase. If thymoquinone arrests 
cells at G(1) it would prevent the cells from entering the M-phase, thus enabling 
paclitaxel from exerting its effect. This was demonstrated in the PA-1 and A172 cells at 
a low drug-drug ratio; however at a 1600:1 ratio in these cells and in all ratios of 
treatment in H460 cells, synergy was seen.  A possible explanation might be that 
thymoquinone is a cell cycle non-specific antineoplastic agent, which is consistent with 
our cell cycle studies.  However, combinations of cell cycle and non-cell cycle agents 
are commonly synergistic regardless of sequence. When the two agents were given 
sequentially with thymoquinone first, the PA-1 and A172 cell lines showed synergy, 
whereas the effect on H460 cells was antagonism. When paclitaxel was administered 
first A172 and H460 cells showed moderate to slight synergism while PA-1 cells showed 
antagonism. While this data does not follow a trend and cannot lead to predictions in 
other cell lines, it is possible to explain why antagonism or synergy could occur. 
Antagonism may result from thymoquinone or paclitaxel halting progression of the cell 
cycle so that the other drug cannot exert its activity at the necessary phase. Synergy 
could be explained if one drug lines up the cells in one phase so that all of the cells in 
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the population progress at the same time to the next phase, thus allowing the second 
drug to kill all of those cells at once. Further experimentation is necessary to 
characterize the exact effects of the thymoquinone-paclitaxel drug interaction.  
 
A significant difference was not seen in the cell cycle distribution analysis of 
thymoquinone treated cells compared to the untreated cells (PA-1 and A172). Cell cycle 
analysis was performed by Shoeib et al. 2002 using thymoquinone in cancer cells. 
These authors found that thymoquinone arrested all cell types tested at the G(1) phase. 
The apparent discrepancies in the results seen in this study may be due to the 
methodology used.  Shoeib et al. analyzed the cells at six hours post-treatment, and 
these cells were treated with extremely high doses of thymoquinone. The study 
conducted herein used micro molar concentrations and the cell cycle analysis was 
performed 48 hours post-treatment. While the results obtained by Shoeib et al. 2002 are 
possibly valid, the methodology may not have been the best. It is possible that the 
cellular distribution seen at six hours in their study may be the result of cellular shock 
and not due to thymoquinone; cells need some time to recovery from cellular shock 
before an appropriate analysis can be undertaken. In addition the drug concentrations 
which they chose to expose the cells to were also very high and not likely achievable in 
human subjects.  
 
A significant difference was not seen in the apoptotic to necrotic ratio. While these 
results are not conclusive, possible explanations may be that the drug concentration 
added was either too high which caused 100% cell death which would not allow for the 
apoptosis analysis or that the concentration added was too low to have an effect on the 
cell viability and apoptosis. It was very difficult to find a median concentration due to a 
threshold effect. The last study set of experiments performed demonstrated a trend 
which, indicates that thymoquinone functions as a cytotoxic agent. This may be 
explained by the increase in p53 which is known to lead to apoptosis. 
 
The studies reported in this thesis support the hypothesis that thymoquinone is indeed a 
cytotoxic agent, which upregulates p53. However, the results gathered in this thesis 
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suggest that this may not be its only mechanism of cytotoxicity. Combination drug 
therapy with thymoquinone seems to be an attractive option, but conflicting results with 
different drugs and the variability between cell lines seem to suggest that this may not 
be a viable alternative. More studies need to be performed with thymoquinone to assess 
the true chemotherapeutic potential of this amazing phytochemical agent. 
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